Viking Therapeutics (VKTX) Debt Ratio (2015 - 2016)

Viking Therapeutics (VKTX) reported Debt Ratio of 0.2 for Q1 2016, up 21.03% sequentially from 0.16 in Q4 2015.

Viking Therapeutics (VKTX) Debt Ratio (2015 - 2016) Analysis & Trends

Viking Therapeutics (VKTX) has 2 years of Debt Ratio data on file, last reported at 0.2 in Q1 2016.

For the quarter ending Q1 2016, Debt Ratio changed N/A year-over-year to 0.2; the trailing twelve-month figure through Mar 2016 stood at 0.2 (changed N/A YoY), and the FY2015 full-year result was 0.16, changed N/A from the prior year.
Debt Ratio grew to 0.2 in Q1 2016, from 0.16 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.2 in Q1 2016 to a low of 0.16 in Q4 2015.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	1.41
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.11
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.05
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Viking Therapeutics	4.09 Bn	4.09 Bn	-	-

Historic Data

Download Data

Date	Value
Mar 31, 2016	0.20
Dec 31, 2015	0.16